Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment
- 10 May 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 27 (10), 907-913
- https://doi.org/10.1007/s10096-008-0519-1
Abstract
The reactivation of latent tuberculosis (TB) is a major complication of tumor necrosis factor (TNF)-α inhibitors. Screening for TB infection is recommended before anti-TNF therapy is initiated; however, the use of tuberculin skin testing (TST) is controversial, due to the high rate of false-negative results in patients receiving immunosuppressive treatment. To compare the performance of two commercial interferon (IFN)-γ release assays (IGRA), T-SPOT.TB (TS-TB) and QuantiFERON-TB Gold “In-tube” (QFT-GIT), with TST for the detection of TB infection in patients due to start anti-TNF therapy, 69 human immunodeficiency virus (HIV)-negative Italian patients (mean age: 45.2 ± 12.6 years; male=39) were enrolled between September 2005 to August 2006. Patients affected by rheumatoid arthritis (n = 18), psoriatic arthritis (n = 26), ulcerous rectocolitis (n = 6), and Crohn’s disease (n = 19) were tested simultaneously with TST, TS-TB, and QFT-GIT. Overall, 26% of patients were positive by TST, 30.4% by TS-TB, and 31.8% by QFT-GIT. Agreement with TST was similar (κ = 0.21, p = 0.0002 and κ = 0.26, p < 0.001, respectively). In 11 TST-negative cases, IFN-γ release assays were positive. In addition, in seven Mantoux-positive cases with no TB risk factors, TST result agreement was achieved with at least one blood test. Indeterminate results were detected in 5.8% and 2.8% of cases, respectively, with TS-TB and with QFT-GIT (p = not significant [ns]). In conclusion, our results suggest that IGRAs may be helpful for screening purposes in patient candidates for anti-TNF therapy to confirm positive TST results and in selected cases when false-negative results are suspected. The utility of blood tests in patients with low or no TB risk remains to be assessed.Keywords
This publication has 40 references indexed in Scilit:
- Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced diseaseClinical and Experimental Immunology, 2007
- Comparison of an Interferon-γ Release Assay with Tuberculin Skin Testing in HIV-infected IndividualsAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Conventional tuberculin skin testing versus T-cell-based assays in the diagnosis of latent tuberculosis infection in HIV-positive patientsAIDS, 2007
- Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factorNature Clinical Practice Rheumatology, 2006
- Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in childrenThorax, 2006
- Does anti-tumour necrosis factor treatment modify the tuberculin PPD response?Annals Of The Rheumatic Diseases, 2006
- Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practiceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- TB screening and anti-TNF treatmentThorax, 2005
- Prospective Evaluation of a Whole-Blood Test Using Mycobacterium tuberculosis -Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active TuberculosisClinical and Vaccine Immunology, 2005
- Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic reviewThe Lancet Infectious Diseases, 2004